Drug Approval | October 13, 2021
Dr Reddy’s launch anti-cancer drug in China
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
Since its inception, the company has either acquired or taken a majority stake in five companies
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
The drug is being developed at lab scale for the first-line of treatment of Covid-19
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
It is one of the first companies to launch a bioequivalent version of the dry powder inhaler and it's part of the company’s strategic exclusive in-licensing arrangement to market Tiotropium DPI in Western Europe and the UK
AZD7442 reduced risk of developing severe Covid-19 or death in Tackle Phase III outpatient treatment trial
The Pune centre expands its presence beyond Bangalore and Hyderabad
The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality
Subscribe To Our Newsletter & Stay Updated
